David Clemow

7PUBLICATIONS
20CO-AUTHORS
Serious gamesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pacific Peoples social, cultural, emotional and spiritual wellbeingMedical mycologyAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 16, 2026
Response to: The Long Game in Ulcerative Colitis: Mirikizumab's Four-Year Outcomes.

|Mar 04, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Bruce E Sands, David B Clemow, Geert D'Haens

|Oct 30, 2024
Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.

David Clemow, Christine Radawski, Joe Milata

|Oct 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Bruce E Sands, Geert D'Haens, David B Clemow

|Mar 09, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Bruce E Sands, Geert D'Haens, David B Clemow

|Feb 13, 2023
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.

Marla C Dubinsky, David B Clemow, Theresa Hunter Gibble

Pageof 2

Frequent Collaborators

3 joint publications

Severine Vermeire

3 joint publications

Tadakazu Hisamatsu

3 joint publications

Taku Kobayashi

2 joint publications

Joe Milata